Literature DB >> 8490924

Multivariate analysis of the relationship between survival and the microstage of primary melanoma by Clark level and Breslow thickness.

D L Morton1, D G Davtyan, L A Wanek, L J Foshag, A J Cochran.   

Abstract

BACKGROUND: The American Joint Committee on Cancer (AJCC) uses both Breslow thickness and Clark level in its staging system for malignant melanoma. Stage I corresponds to Breslow thicknesses less than 1.5 mm and Clark levels II and III. Stage II corresponds to Breslow thicknesses of at least 1.5 mm and Clark levels IV and V. However, most investigators have found Clark level to be of no prognostic significance once Breslow thickness has been taken into consideration by multivariate analysis.
METHODS: The authors examined the prognostic significance of Clark level by studying patients in the large database of the John Wayne Cancer Institute. Among 5575 patients with melanoma seen during the past 20 years, complete data on microstaging by both Clark and Breslow methods were available for 3323 patients. The 5-year survival rates were as follows: Clark II, 95%; III, 81%; IV, 68%; V, 47%. The Breslow thicknesses were as follows: < 0.75 mm, 95%; 0.75-1.49 mm, 85%; 1.5-3.99 mm, 66%; > or = 4.0 mm, 46%.
RESULTS: By univariate analysis, both Clark level and Breslow thickness were highly significant prognostic indicators (P < 0.0001). By multivariate analysis, Breslow thickness remained significant (P < 0.0001). However, even when Breslow thickness was included in the model, Clark level also remained highly significant (P < 0.0015).
CONCLUSIONS: Decisions regarding therapy for patients with clinical Stage I melanoma should consider both Clark level and Breslow thickness of the primary lesion. When there is a discordance between the two methods of microstaging, the AJCC stage should be amended to reflect the least favorable of the two prognostic indicators.

Entities:  

Mesh:

Year:  1993        PMID: 8490924     DOI: 10.1002/1097-0142(19930601)71:11<3737::aid-cncr2820711143>3.0.co;2-7

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

Review 1.  The KISS1 metastasis suppressor: mechanistic insights and clinical utility.

Authors:  Kevin T Nash; Danny R Welch
Journal:  Front Biosci       Date:  2006-01-01

Review 2.  Staging and prognosis of cutaneous melanoma.

Authors:  Paxton V Dickson; Jeffrey E Gershenwald
Journal:  Surg Oncol Clin N Am       Date:  2011-01       Impact factor: 3.495

3.  Clinical significance of occult metastatic melanoma in sentinel lymph nodes and other high-risk factors based on long-term follow-up.

Authors:  Stanley P L Leong; Mohammed Kashani-Sabet; Renee A Desmond; Robert P Kim; Dennis H Nguyen; Kensho Iwanaga; Patrick A Treseler; Robert E Allen; Eugene T Morita; Yuting Zhang; Richard W Sagebiel; Seng-Jaw Soong
Journal:  World J Surg       Date:  2005-06       Impact factor: 3.352

4.  Treatment and outcomes of melanoma in acral location in Korean patients.

Authors:  Mi Ryung Roh; Jihyun Kim; Kee Yang Chung
Journal:  Yonsei Med J       Date:  2010-07       Impact factor: 2.759

5.  Preliminary results on the use of a noninvasive instrument for the evaluation of the depth of pigmented skin lesions: numerical simulations and experimental measurements.

Authors:  Alida Mazzoli; Roberto Munaretto; Lorenzo Scalise
Journal:  Lasers Med Sci       Date:  2009-09-08       Impact factor: 3.161

6.  Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm.

Authors:  Neta Tsur; Yuri Kogan; Evgenia Avizov-Khodak; Désirée Vaeth; Nils Vogler; Jochen Utikal; Michal Lotem; Zvia Agur
Journal:  J Transl Med       Date:  2019-10-07       Impact factor: 5.531

Review 7.  Tailoring the Treatment of Melanoma: Implications for Personalized Medicine.

Authors:  Linna Duan; Eric M Mukherjee; Deepak Narayan
Journal:  Yale J Biol Med       Date:  2015-11-24

8.  Biomechanical interplay between anisotropic re-organization of cells and the surrounding matrix underlies transition to invasive cancer spread.

Authors:  Deok-Ho Kim; Andrew J Ewald; JinSeok Park; Moonkyu Kwak; Ryan S Gray; Chia-Yi Su; Jayhyun Seo; Steven S An; Andre Levchenko
Journal:  Sci Rep       Date:  2018-09-21       Impact factor: 4.379

9.  Development of a Four-mRNA Expression-Based Prognostic Signature for Cutaneous Melanoma.

Authors:  Haiya Bai; Youliang Wang; Huimin Liu; Junyang Lu
Journal:  Front Genet       Date:  2021-07-15       Impact factor: 4.599

10.  The relationship between mitotic rate and depth of invasion in biopsies of malignant melanoma.

Authors:  Hamid Reza Ghasemi Basir; Pedram Alirezaei; Sara Ahovan; Abbas Moradi
Journal:  Clin Cosmet Investig Dermatol       Date:  2018-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.